Investment

Features

Fees Safety

Academy

Pluang+

Home/News Feed/BridgeBio to report Q2 2026 financial results and updates on August 10, 2026

BBIO

$84.48

+$1.68 +2.03%

BridgeBio to report Q2 2026 financial results and updates on August 10, 2026

Company Fundamentals

03 Aug 2026

GlobeNewsWire

View Source

Neutral

BridgeBio Pharma, a biopharmaceutical company specializing in genetic condition treatments, will announce its second quarter 2026 financial results and business updates on August 10, 2026, after market close. The company will hold a conference call at 4:30 pm ET the same day to discuss these results and program developments. Investors can access the live webcast on BridgeBio's website, with a replay available for 30 days. This update is important as BridgeBio continues advancing medicines for underserved genetic conditions, including recent progress with its drug encaleret for ADH1.

More News (BBIO)

BridgeBio Pharma eyes growth with Q2 results and FDA review of new drug encaleret

BridgeBio Pharma is set to report its Q2 earnings on August 10, 2026, with analysts expecting $220.91 million in revenue and a loss of $0.63 per share. The FDA recently accepted the New Drug Application for encaleret, targeting a rare genetic conditi...

Company Fundamentals

Bullish

4 days ago